Global Cancer Biologics Market Research Report 2024, Forecast to 2032
Report Overview
Cancer Biologic is a medicinal preparation created by a biological process, it is used to treatment and remission cancer symptoms.
The global Cancer Biologics market size was estimated at USD 161690 million in 2023 and is projected to reach USD 466719.41 million by 2032, exhibiting a CAGR of 12.50% during the forecast period.
North America Cancer Biologics market size was estimated at USD 51643.69 million in 2023, at a CAGR of 10.71% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Cancer Biologics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cancer Biologics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cancer Biologics market in any manner.
Global Cancer Biologics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Market Segmentation (by Type)
Monoclonal Antibodies
Vaccines
Cell and Gene Therapy
Others
Market Segmentation (by Application)
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cancer Biologics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Cancer Biologics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
Cancer Biologic is a medicinal preparation created by a biological process, it is used to treatment and remission cancer symptoms.
The global Cancer Biologics market size was estimated at USD 161690 million in 2023 and is projected to reach USD 466719.41 million by 2032, exhibiting a CAGR of 12.50% during the forecast period.
North America Cancer Biologics market size was estimated at USD 51643.69 million in 2023, at a CAGR of 10.71% during the forecast period of 2024 through 2032.
This report provides a deep insight into the global Cancer Biologics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cancer Biologics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cancer Biologics market in any manner.
Global Cancer Biologics Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
AbbVie
Johnson & Johnson
Novartis
Gilead Sciences
Roche
Bristol-Myers Squibb
Amgen
AstraZeneca
Merck & Co
Takeda
Merck KGaA
Seagen
Eli Lilly
Ono Pharmaceutical
Pfizer
GSK
Exelixis
Regeneron
Innovent
Hengrui Medicine
Market Segmentation (by Type)
Monoclonal Antibodies
Vaccines
Cell and Gene Therapy
Others
Market Segmentation (by Application)
Lung Cancer
Breast Cancer
Prostate Cancer
Blood-related Cancer
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Cancer Biologics Market
- Overview of the regional outlook of the Cancer Biologics Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cancer Biologics Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Cancer Biologics, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
Chapter 13 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Cancer Biologics
1.2 Key Market Segments
1.2.1 Cancer Biologics Segment by Type
1.2.2 Cancer Biologics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CANCER BIOLOGICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Cancer Biologics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Cancer Biologics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CANCER BIOLOGICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Cancer Biologics Sales by Manufacturers (2019-2024)
3.2 Global Cancer Biologics Revenue Market Share by Manufacturers (2019-2024)
3.3 Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Cancer Biologics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Cancer Biologics Sales Sites, Area Served, Product Type
3.6 Cancer Biologics Market Competitive Situation and Trends
3.6.1 Cancer Biologics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Cancer Biologics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CANCER BIOLOGICS INDUSTRY CHAIN ANALYSIS
4.1 Cancer Biologics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CANCER BIOLOGICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CANCER BIOLOGICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cancer Biologics Sales Market Share by Type (2019-2024)
6.3 Global Cancer Biologics Market Size Market Share by Type (2019-2024)
6.4 Global Cancer Biologics Price by Type (2019-2024)
7 CANCER BIOLOGICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cancer Biologics Market Sales by Application (2019-2024)
7.3 Global Cancer Biologics Market Size (M USD) by Application (2019-2024)
7.4 Global Cancer Biologics Sales Growth Rate by Application (2019-2024)
8 CANCER BIOLOGICS MARKET CONSUMPTION BY REGION
8.1 Global Cancer Biologics Sales by Region
8.1.1 Global Cancer Biologics Sales by Region
8.1.2 Global Cancer Biologics Sales Market Share by Region
8.2 North America
8.2.1 North America Cancer Biologics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cancer Biologics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cancer Biologics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cancer Biologics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cancer Biologics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 CANCER BIOLOGICS MARKET PRODUCTION BY REGION
9.1 Global Production of Cancer Biologics by Region (2019-2024)
9.2 Global Cancer Biologics Revenue Market Share by Region (2019-2024)
9.3 Global Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Cancer Biologics Production
9.4.1 North America Cancer Biologics Production Growth Rate (2019-2024)
9.4.2 North America Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Cancer Biologics Production
9.5.1 Europe Cancer Biologics Production Growth Rate (2019-2024)
9.5.2 Europe Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Cancer Biologics Production (2019-2024)
9.6.1 Japan Cancer Biologics Production Growth Rate (2019-2024)
9.6.2 Japan Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Cancer Biologics Production (2019-2024)
9.7.1 China Cancer Biologics Production Growth Rate (2019-2024)
9.7.2 China Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 AbbVie
10.1.1 AbbVie Cancer Biologics Basic Information
10.1.2 AbbVie Cancer Biologics Product Overview
10.1.3 AbbVie Cancer Biologics Product Market Performance
10.1.4 AbbVie Business Overview
10.1.5 AbbVie Cancer Biologics SWOT Analysis
10.1.6 AbbVie Recent Developments
10.2 Johnson and Johnson
10.2.1 Johnson and Johnson Cancer Biologics Basic Information
10.2.2 Johnson and Johnson Cancer Biologics Product Overview
10.2.3 Johnson and Johnson Cancer Biologics Product Market Performance
10.2.4 Johnson and Johnson Business Overview
10.2.5 Johnson and Johnson Cancer Biologics SWOT Analysis
10.2.6 Johnson and Johnson Recent Developments
10.3 Novartis
10.3.1 Novartis Cancer Biologics Basic Information
10.3.2 Novartis Cancer Biologics Product Overview
10.3.3 Novartis Cancer Biologics Product Market Performance
10.3.4 Novartis Cancer Biologics SWOT Analysis
10.3.5 Novartis Business Overview
10.3.6 Novartis Recent Developments
10.4 Gilead Sciences
10.4.1 Gilead Sciences Cancer Biologics Basic Information
10.4.2 Gilead Sciences Cancer Biologics Product Overview
10.4.3 Gilead Sciences Cancer Biologics Product Market Performance
10.4.4 Gilead Sciences Business Overview
10.4.5 Gilead Sciences Recent Developments
10.5 Roche
10.5.1 Roche Cancer Biologics Basic Information
10.5.2 Roche Cancer Biologics Product Overview
10.5.3 Roche Cancer Biologics Product Market Performance
10.5.4 Roche Business Overview
10.5.5 Roche Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Cancer Biologics Basic Information
10.6.2 Bristol-Myers Squibb Cancer Biologics Product Overview
10.6.3 Bristol-Myers Squibb Cancer Biologics Product Market Performance
10.6.4 Bristol-Myers Squibb Business Overview
10.6.5 Bristol-Myers Squibb Recent Developments
10.7 Amgen
10.7.1 Amgen Cancer Biologics Basic Information
10.7.2 Amgen Cancer Biologics Product Overview
10.7.3 Amgen Cancer Biologics Product Market Performance
10.7.4 Amgen Business Overview
10.7.5 Amgen Recent Developments
10.8 AstraZeneca
10.8.1 AstraZeneca Cancer Biologics Basic Information
10.8.2 AstraZeneca Cancer Biologics Product Overview
10.8.3 AstraZeneca Cancer Biologics Product Market Performance
10.8.4 AstraZeneca Business Overview
10.8.5 AstraZeneca Recent Developments
10.9 Merck and Co
10.9.1 Merck and Co Cancer Biologics Basic Information
10.9.2 Merck and Co Cancer Biologics Product Overview
10.9.3 Merck and Co Cancer Biologics Product Market Performance
10.9.4 Merck and Co Business Overview
10.9.5 Merck and Co Recent Developments
10.10 Takeda
10.10.1 Takeda Cancer Biologics Basic Information
10.10.2 Takeda Cancer Biologics Product Overview
10.10.3 Takeda Cancer Biologics Product Market Performance
10.10.4 Takeda Business Overview
10.10.5 Takeda Recent Developments
10.11 Merck KGaA
10.11.1 Merck KGaA Cancer Biologics Basic Information
10.11.2 Merck KGaA Cancer Biologics Product Overview
10.11.3 Merck KGaA Cancer Biologics Product Market Performance
10.11.4 Merck KGaA Business Overview
10.11.5 Merck KGaA Recent Developments
10.12 Seagen
10.12.1 Seagen Cancer Biologics Basic Information
10.12.2 Seagen Cancer Biologics Product Overview
10.12.3 Seagen Cancer Biologics Product Market Performance
10.12.4 Seagen Business Overview
10.12.5 Seagen Recent Developments
10.13 Eli Lilly
10.13.1 Eli Lilly Cancer Biologics Basic Information
10.13.2 Eli Lilly Cancer Biologics Product Overview
10.13.3 Eli Lilly Cancer Biologics Product Market Performance
10.13.4 Eli Lilly Business Overview
10.13.5 Eli Lilly Recent Developments
10.14 Ono Pharmaceutical
10.14.1 Ono Pharmaceutical Cancer Biologics Basic Information
10.14.2 Ono Pharmaceutical Cancer Biologics Product Overview
10.14.3 Ono Pharmaceutical Cancer Biologics Product Market Performance
10.14.4 Ono Pharmaceutical Business Overview
10.14.5 Ono Pharmaceutical Recent Developments
10.15 Pfizer
10.15.1 Pfizer Cancer Biologics Basic Information
10.15.2 Pfizer Cancer Biologics Product Overview
10.15.3 Pfizer Cancer Biologics Product Market Performance
10.15.4 Pfizer Business Overview
10.15.5 Pfizer Recent Developments
10.16 GSK
10.16.1 GSK Cancer Biologics Basic Information
10.16.2 GSK Cancer Biologics Product Overview
10.16.3 GSK Cancer Biologics Product Market Performance
10.16.4 GSK Business Overview
10.16.5 GSK Recent Developments
10.17 Exelixis
10.17.1 Exelixis Cancer Biologics Basic Information
10.17.2 Exelixis Cancer Biologics Product Overview
10.17.3 Exelixis Cancer Biologics Product Market Performance
10.17.4 Exelixis Business Overview
10.17.5 Exelixis Recent Developments
10.18 Regeneron
10.18.1 Regeneron Cancer Biologics Basic Information
10.18.2 Regeneron Cancer Biologics Product Overview
10.18.3 Regeneron Cancer Biologics Product Market Performance
10.18.4 Regeneron Business Overview
10.18.5 Regeneron Recent Developments
10.19 Innovent
10.19.1 Innovent Cancer Biologics Basic Information
10.19.2 Innovent Cancer Biologics Product Overview
10.19.3 Innovent Cancer Biologics Product Market Performance
10.19.4 Innovent Business Overview
10.19.5 Innovent Recent Developments
10.20 Hengrui Medicine
10.20.1 Hengrui Medicine Cancer Biologics Basic Information
10.20.2 Hengrui Medicine Cancer Biologics Product Overview
10.20.3 Hengrui Medicine Cancer Biologics Product Market Performance
10.20.4 Hengrui Medicine Business Overview
10.20.5 Hengrui Medicine Recent Developments
11 CANCER BIOLOGICS MARKET FORECAST BY REGION
11.1 Global Cancer Biologics Market Size Forecast
11.2 Global Cancer Biologics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Cancer Biologics Market Size Forecast by Country
11.2.3 Asia Pacific Cancer Biologics Market Size Forecast by Region
11.2.4 South America Cancer Biologics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Cancer Biologics by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Cancer Biologics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Cancer Biologics by Type (2025-2032)
12.1.2 Global Cancer Biologics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Cancer Biologics by Type (2025-2032)
12.2 Global Cancer Biologics Market Forecast by Application (2025-2032)
12.2.1 Global Cancer Biologics Sales (K Units) Forecast by Application
12.2.2 Global Cancer Biologics Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Cancer Biologics
1.2 Key Market Segments
1.2.1 Cancer Biologics Segment by Type
1.2.2 Cancer Biologics Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CANCER BIOLOGICS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Cancer Biologics Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Cancer Biologics Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CANCER BIOLOGICS MARKET COMPETITIVE LANDSCAPE
3.1 Global Cancer Biologics Sales by Manufacturers (2019-2024)
3.2 Global Cancer Biologics Revenue Market Share by Manufacturers (2019-2024)
3.3 Cancer Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Cancer Biologics Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Cancer Biologics Sales Sites, Area Served, Product Type
3.6 Cancer Biologics Market Competitive Situation and Trends
3.6.1 Cancer Biologics Market Concentration Rate
3.6.2 Global 5 and 10 Largest Cancer Biologics Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 CANCER BIOLOGICS INDUSTRY CHAIN ANALYSIS
4.1 Cancer Biologics Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CANCER BIOLOGICS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 CANCER BIOLOGICS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cancer Biologics Sales Market Share by Type (2019-2024)
6.3 Global Cancer Biologics Market Size Market Share by Type (2019-2024)
6.4 Global Cancer Biologics Price by Type (2019-2024)
7 CANCER BIOLOGICS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cancer Biologics Market Sales by Application (2019-2024)
7.3 Global Cancer Biologics Market Size (M USD) by Application (2019-2024)
7.4 Global Cancer Biologics Sales Growth Rate by Application (2019-2024)
8 CANCER BIOLOGICS MARKET CONSUMPTION BY REGION
8.1 Global Cancer Biologics Sales by Region
8.1.1 Global Cancer Biologics Sales by Region
8.1.2 Global Cancer Biologics Sales Market Share by Region
8.2 North America
8.2.1 North America Cancer Biologics Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cancer Biologics Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cancer Biologics Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cancer Biologics Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cancer Biologics Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 CANCER BIOLOGICS MARKET PRODUCTION BY REGION
9.1 Global Production of Cancer Biologics by Region (2019-2024)
9.2 Global Cancer Biologics Revenue Market Share by Region (2019-2024)
9.3 Global Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.4 North America Cancer Biologics Production
9.4.1 North America Cancer Biologics Production Growth Rate (2019-2024)
9.4.2 North America Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.5 Europe Cancer Biologics Production
9.5.1 Europe Cancer Biologics Production Growth Rate (2019-2024)
9.5.2 Europe Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.6 Japan Cancer Biologics Production (2019-2024)
9.6.1 Japan Cancer Biologics Production Growth Rate (2019-2024)
9.6.2 Japan Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
9.7 China Cancer Biologics Production (2019-2024)
9.7.1 China Cancer Biologics Production Growth Rate (2019-2024)
9.7.2 China Cancer Biologics Production, Revenue, Price and Gross Margin (2019-2024)
10 KEY COMPANIES PROFILE
10.1 AbbVie
10.1.1 AbbVie Cancer Biologics Basic Information
10.1.2 AbbVie Cancer Biologics Product Overview
10.1.3 AbbVie Cancer Biologics Product Market Performance
10.1.4 AbbVie Business Overview
10.1.5 AbbVie Cancer Biologics SWOT Analysis
10.1.6 AbbVie Recent Developments
10.2 Johnson and Johnson
10.2.1 Johnson and Johnson Cancer Biologics Basic Information
10.2.2 Johnson and Johnson Cancer Biologics Product Overview
10.2.3 Johnson and Johnson Cancer Biologics Product Market Performance
10.2.4 Johnson and Johnson Business Overview
10.2.5 Johnson and Johnson Cancer Biologics SWOT Analysis
10.2.6 Johnson and Johnson Recent Developments
10.3 Novartis
10.3.1 Novartis Cancer Biologics Basic Information
10.3.2 Novartis Cancer Biologics Product Overview
10.3.3 Novartis Cancer Biologics Product Market Performance
10.3.4 Novartis Cancer Biologics SWOT Analysis
10.3.5 Novartis Business Overview
10.3.6 Novartis Recent Developments
10.4 Gilead Sciences
10.4.1 Gilead Sciences Cancer Biologics Basic Information
10.4.2 Gilead Sciences Cancer Biologics Product Overview
10.4.3 Gilead Sciences Cancer Biologics Product Market Performance
10.4.4 Gilead Sciences Business Overview
10.4.5 Gilead Sciences Recent Developments
10.5 Roche
10.5.1 Roche Cancer Biologics Basic Information
10.5.2 Roche Cancer Biologics Product Overview
10.5.3 Roche Cancer Biologics Product Market Performance
10.5.4 Roche Business Overview
10.5.5 Roche Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Bristol-Myers Squibb Cancer Biologics Basic Information
10.6.2 Bristol-Myers Squibb Cancer Biologics Product Overview
10.6.3 Bristol-Myers Squibb Cancer Biologics Product Market Performance
10.6.4 Bristol-Myers Squibb Business Overview
10.6.5 Bristol-Myers Squibb Recent Developments
10.7 Amgen
10.7.1 Amgen Cancer Biologics Basic Information
10.7.2 Amgen Cancer Biologics Product Overview
10.7.3 Amgen Cancer Biologics Product Market Performance
10.7.4 Amgen Business Overview
10.7.5 Amgen Recent Developments
10.8 AstraZeneca
10.8.1 AstraZeneca Cancer Biologics Basic Information
10.8.2 AstraZeneca Cancer Biologics Product Overview
10.8.3 AstraZeneca Cancer Biologics Product Market Performance
10.8.4 AstraZeneca Business Overview
10.8.5 AstraZeneca Recent Developments
10.9 Merck and Co
10.9.1 Merck and Co Cancer Biologics Basic Information
10.9.2 Merck and Co Cancer Biologics Product Overview
10.9.3 Merck and Co Cancer Biologics Product Market Performance
10.9.4 Merck and Co Business Overview
10.9.5 Merck and Co Recent Developments
10.10 Takeda
10.10.1 Takeda Cancer Biologics Basic Information
10.10.2 Takeda Cancer Biologics Product Overview
10.10.3 Takeda Cancer Biologics Product Market Performance
10.10.4 Takeda Business Overview
10.10.5 Takeda Recent Developments
10.11 Merck KGaA
10.11.1 Merck KGaA Cancer Biologics Basic Information
10.11.2 Merck KGaA Cancer Biologics Product Overview
10.11.3 Merck KGaA Cancer Biologics Product Market Performance
10.11.4 Merck KGaA Business Overview
10.11.5 Merck KGaA Recent Developments
10.12 Seagen
10.12.1 Seagen Cancer Biologics Basic Information
10.12.2 Seagen Cancer Biologics Product Overview
10.12.3 Seagen Cancer Biologics Product Market Performance
10.12.4 Seagen Business Overview
10.12.5 Seagen Recent Developments
10.13 Eli Lilly
10.13.1 Eli Lilly Cancer Biologics Basic Information
10.13.2 Eli Lilly Cancer Biologics Product Overview
10.13.3 Eli Lilly Cancer Biologics Product Market Performance
10.13.4 Eli Lilly Business Overview
10.13.5 Eli Lilly Recent Developments
10.14 Ono Pharmaceutical
10.14.1 Ono Pharmaceutical Cancer Biologics Basic Information
10.14.2 Ono Pharmaceutical Cancer Biologics Product Overview
10.14.3 Ono Pharmaceutical Cancer Biologics Product Market Performance
10.14.4 Ono Pharmaceutical Business Overview
10.14.5 Ono Pharmaceutical Recent Developments
10.15 Pfizer
10.15.1 Pfizer Cancer Biologics Basic Information
10.15.2 Pfizer Cancer Biologics Product Overview
10.15.3 Pfizer Cancer Biologics Product Market Performance
10.15.4 Pfizer Business Overview
10.15.5 Pfizer Recent Developments
10.16 GSK
10.16.1 GSK Cancer Biologics Basic Information
10.16.2 GSK Cancer Biologics Product Overview
10.16.3 GSK Cancer Biologics Product Market Performance
10.16.4 GSK Business Overview
10.16.5 GSK Recent Developments
10.17 Exelixis
10.17.1 Exelixis Cancer Biologics Basic Information
10.17.2 Exelixis Cancer Biologics Product Overview
10.17.3 Exelixis Cancer Biologics Product Market Performance
10.17.4 Exelixis Business Overview
10.17.5 Exelixis Recent Developments
10.18 Regeneron
10.18.1 Regeneron Cancer Biologics Basic Information
10.18.2 Regeneron Cancer Biologics Product Overview
10.18.3 Regeneron Cancer Biologics Product Market Performance
10.18.4 Regeneron Business Overview
10.18.5 Regeneron Recent Developments
10.19 Innovent
10.19.1 Innovent Cancer Biologics Basic Information
10.19.2 Innovent Cancer Biologics Product Overview
10.19.3 Innovent Cancer Biologics Product Market Performance
10.19.4 Innovent Business Overview
10.19.5 Innovent Recent Developments
10.20 Hengrui Medicine
10.20.1 Hengrui Medicine Cancer Biologics Basic Information
10.20.2 Hengrui Medicine Cancer Biologics Product Overview
10.20.3 Hengrui Medicine Cancer Biologics Product Market Performance
10.20.4 Hengrui Medicine Business Overview
10.20.5 Hengrui Medicine Recent Developments
11 CANCER BIOLOGICS MARKET FORECAST BY REGION
11.1 Global Cancer Biologics Market Size Forecast
11.2 Global Cancer Biologics Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Cancer Biologics Market Size Forecast by Country
11.2.3 Asia Pacific Cancer Biologics Market Size Forecast by Region
11.2.4 South America Cancer Biologics Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Cancer Biologics by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)
12.1 Global Cancer Biologics Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Cancer Biologics by Type (2025-2032)
12.1.2 Global Cancer Biologics Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Cancer Biologics by Type (2025-2032)
12.2 Global Cancer Biologics Market Forecast by Application (2025-2032)
12.2.1 Global Cancer Biologics Sales (K Units) Forecast by Application
12.2.2 Global Cancer Biologics Market Size (M USD) Forecast by Application (2025-2032)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cancer Biologics Market Size Comparison by Region (M USD)
Table 5. Global Cancer Biologics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Cancer Biologics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Cancer Biologics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Cancer Biologics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biologics as of 2022)
Table 10. Global Market Cancer Biologics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Cancer Biologics Sales Sites and Area Served
Table 12. Manufacturers Cancer Biologics Product Type
Table 13. Global Cancer Biologics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Cancer Biologics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Cancer Biologics Market Challenges
Table 22. Global Cancer Biologics Sales by Type (K Units)
Table 23. Global Cancer Biologics Market Size by Type (M USD)
Table 24. Global Cancer Biologics Sales (K Units) by Type (2019-2024)
Table 25. Global Cancer Biologics Sales Market Share by Type (2019-2024)
Table 26. Global Cancer Biologics Market Size (M USD) by Type (2019-2024)
Table 27. Global Cancer Biologics Market Size Share by Type (2019-2024)
Table 28. Global Cancer Biologics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Cancer Biologics Sales (K Units) by Application
Table 30. Global Cancer Biologics Market Size by Application
Table 31. Global Cancer Biologics Sales by Application (2019-2024) & (K Units)
Table 32. Global Cancer Biologics Sales Market Share by Application (2019-2024)
Table 33. Global Cancer Biologics Sales by Application (2019-2024) & (M USD)
Table 34. Global Cancer Biologics Market Share by Application (2019-2024)
Table 35. Global Cancer Biologics Sales Growth Rate by Application (2019-2024)
Table 36. Global Cancer Biologics Sales by Region (2019-2024) & (K Units)
Table 37. Global Cancer Biologics Sales Market Share by Region (2019-2024)
Table 38. North America Cancer Biologics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Cancer Biologics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Cancer Biologics Sales by Region (2019-2024) & (K Units)
Table 41. South America Cancer Biologics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Cancer Biologics Sales by Region (2019-2024) & (K Units)
Table 43. Global Cancer Biologics Production (K Units) by Region (2019-2024)
Table 44. Global Cancer Biologics Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Cancer Biologics Revenue Market Share by Region (2019-2024)
Table 46. Global Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 47. North America Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 48. Europe Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Japan Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 50. China Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 51. AbbVie Cancer Biologics Basic Information
Table 52. AbbVie Cancer Biologics Product Overview
Table 53. AbbVie Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 54. AbbVie Business Overview
Table 55. AbbVie Cancer Biologics SWOT Analysis
Table 56. AbbVie Recent Developments
Table 57. Johnson and Johnson Cancer Biologics Basic Information
Table 58. Johnson and Johnson Cancer Biologics Product Overview
Table 59. Johnson and Johnson Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 60. Johnson and Johnson Business Overview
Table 61. Johnson and Johnson Cancer Biologics SWOT Analysis
Table 62. Johnson and Johnson Recent Developments
Table 63. Novartis Cancer Biologics Basic Information
Table 64. Novartis Cancer Biologics Product Overview
Table 65. Novartis Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 66. Novartis Cancer Biologics SWOT Analysis
Table 67. Novartis Business Overview
Table 68. Novartis Recent Developments
Table 69. Gilead Sciences Cancer Biologics Basic Information
Table 70. Gilead Sciences Cancer Biologics Product Overview
Table 71. Gilead Sciences Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 72. Gilead Sciences Business Overview
Table 73. Gilead Sciences Recent Developments
Table 74. Roche Cancer Biologics Basic Information
Table 75. Roche Cancer Biologics Product Overview
Table 76. Roche Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 77. Roche Business Overview
Table 78. Roche Recent Developments
Table 79. Bristol-Myers Squibb Cancer Biologics Basic Information
Table 80. Bristol-Myers Squibb Cancer Biologics Product Overview
Table 81. Bristol-Myers Squibb Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Recent Developments
Table 84. Amgen Cancer Biologics Basic Information
Table 85. Amgen Cancer Biologics Product Overview
Table 86. Amgen Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Amgen Business Overview
Table 88. Amgen Recent Developments
Table 89. AstraZeneca Cancer Biologics Basic Information
Table 90. AstraZeneca Cancer Biologics Product Overview
Table 91. AstraZeneca Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. AstraZeneca Business Overview
Table 93. AstraZeneca Recent Developments
Table 94. Merck and Co Cancer Biologics Basic Information
Table 95. Merck and Co Cancer Biologics Product Overview
Table 96. Merck and Co Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Merck and Co Business Overview
Table 98. Merck and Co Recent Developments
Table 99. Takeda Cancer Biologics Basic Information
Table 100. Takeda Cancer Biologics Product Overview
Table 101. Takeda Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 102. Takeda Business Overview
Table 103. Takeda Recent Developments
Table 104. Merck KGaA Cancer Biologics Basic Information
Table 105. Merck KGaA Cancer Biologics Product Overview
Table 106. Merck KGaA Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Recent Developments
Table 109. Seagen Cancer Biologics Basic Information
Table 110. Seagen Cancer Biologics Product Overview
Table 111. Seagen Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 112. Seagen Business Overview
Table 113. Seagen Recent Developments
Table 114. Eli Lilly Cancer Biologics Basic Information
Table 115. Eli Lilly Cancer Biologics Product Overview
Table 116. Eli Lilly Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 117. Eli Lilly Business Overview
Table 118. Eli Lilly Recent Developments
Table 119. Ono Pharmaceutical Cancer Biologics Basic Information
Table 120. Ono Pharmaceutical Cancer Biologics Product Overview
Table 121. Ono Pharmaceutical Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 122. Ono Pharmaceutical Business Overview
Table 123. Ono Pharmaceutical Recent Developments
Table 124. Pfizer Cancer Biologics Basic Information
Table 125. Pfizer Cancer Biologics Product Overview
Table 126. Pfizer Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 127. Pfizer Business Overview
Table 128. Pfizer Recent Developments
Table 129. GSK Cancer Biologics Basic Information
Table 130. GSK Cancer Biologics Product Overview
Table 131. GSK Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 132. GSK Business Overview
Table 133. GSK Recent Developments
Table 134. Exelixis Cancer Biologics Basic Information
Table 135. Exelixis Cancer Biologics Product Overview
Table 136. Exelixis Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 137. Exelixis Business Overview
Table 138. Exelixis Recent Developments
Table 139. Regeneron Cancer Biologics Basic Information
Table 140. Regeneron Cancer Biologics Product Overview
Table 141. Regeneron Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 142. Regeneron Business Overview
Table 143. Regeneron Recent Developments
Table 144. Innovent Cancer Biologics Basic Information
Table 145. Innovent Cancer Biologics Product Overview
Table 146. Innovent Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 147. Innovent Business Overview
Table 148. Innovent Recent Developments
Table 149. Hengrui Medicine Cancer Biologics Basic Information
Table 150. Hengrui Medicine Cancer Biologics Product Overview
Table 151. Hengrui Medicine Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 152. Hengrui Medicine Business Overview
Table 153. Hengrui Medicine Recent Developments
Table 154. Global Cancer Biologics Sales Forecast by Region (2025-2032) & (K Units)
Table 155. Global Cancer Biologics Market Size Forecast by Region (2025-2032) & (M USD)
Table 156. North America Cancer Biologics Sales Forecast by Country (2025-2032) & (K Units)
Table 157. North America Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 158. Europe Cancer Biologics Sales Forecast by Country (2025-2032) & (K Units)
Table 159. Europe Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 160. Asia Pacific Cancer Biologics Sales Forecast by Region (2025-2032) & (K Units)
Table 161. Asia Pacific Cancer Biologics Market Size Forecast by Region (2025-2032) & (M USD)
Table 162. South America Cancer Biologics Sales Forecast by Country (2025-2032) & (K Units)
Table 163. South America Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 164. Middle East and Africa Cancer Biologics Consumption Forecast by Country (2025-2032) & (Units)
Table 165. Middle East and Africa Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 166. Global Cancer Biologics Sales Forecast by Type (2025-2032) & (K Units)
Table 167. Global Cancer Biologics Market Size Forecast by Type (2025-2032) & (M USD)
Table 168. Global Cancer Biologics Price Forecast by Type (2025-2032) & (USD/Unit)
Table 169. Global Cancer Biologics Sales (K Units) Forecast by Application (2025-2032)
Table 170. Global Cancer Biologics Market Size Forecast by Application (2025-2032) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cancer Biologics Market Size Comparison by Region (M USD)
Table 5. Global Cancer Biologics Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Cancer Biologics Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Cancer Biologics Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Cancer Biologics Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Biologics as of 2022)
Table 10. Global Market Cancer Biologics Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Cancer Biologics Sales Sites and Area Served
Table 12. Manufacturers Cancer Biologics Product Type
Table 13. Global Cancer Biologics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Cancer Biologics
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Cancer Biologics Market Challenges
Table 22. Global Cancer Biologics Sales by Type (K Units)
Table 23. Global Cancer Biologics Market Size by Type (M USD)
Table 24. Global Cancer Biologics Sales (K Units) by Type (2019-2024)
Table 25. Global Cancer Biologics Sales Market Share by Type (2019-2024)
Table 26. Global Cancer Biologics Market Size (M USD) by Type (2019-2024)
Table 27. Global Cancer Biologics Market Size Share by Type (2019-2024)
Table 28. Global Cancer Biologics Price (USD/Unit) by Type (2019-2024)
Table 29. Global Cancer Biologics Sales (K Units) by Application
Table 30. Global Cancer Biologics Market Size by Application
Table 31. Global Cancer Biologics Sales by Application (2019-2024) & (K Units)
Table 32. Global Cancer Biologics Sales Market Share by Application (2019-2024)
Table 33. Global Cancer Biologics Sales by Application (2019-2024) & (M USD)
Table 34. Global Cancer Biologics Market Share by Application (2019-2024)
Table 35. Global Cancer Biologics Sales Growth Rate by Application (2019-2024)
Table 36. Global Cancer Biologics Sales by Region (2019-2024) & (K Units)
Table 37. Global Cancer Biologics Sales Market Share by Region (2019-2024)
Table 38. North America Cancer Biologics Sales by Country (2019-2024) & (K Units)
Table 39. Europe Cancer Biologics Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Cancer Biologics Sales by Region (2019-2024) & (K Units)
Table 41. South America Cancer Biologics Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Cancer Biologics Sales by Region (2019-2024) & (K Units)
Table 43. Global Cancer Biologics Production (K Units) by Region (2019-2024)
Table 44. Global Cancer Biologics Revenue (US$ Million) by Region (2019-2024)
Table 45. Global Cancer Biologics Revenue Market Share by Region (2019-2024)
Table 46. Global Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 47. North America Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 48. Europe Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 49. Japan Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 50. China Cancer Biologics Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 51. AbbVie Cancer Biologics Basic Information
Table 52. AbbVie Cancer Biologics Product Overview
Table 53. AbbVie Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 54. AbbVie Business Overview
Table 55. AbbVie Cancer Biologics SWOT Analysis
Table 56. AbbVie Recent Developments
Table 57. Johnson and Johnson Cancer Biologics Basic Information
Table 58. Johnson and Johnson Cancer Biologics Product Overview
Table 59. Johnson and Johnson Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 60. Johnson and Johnson Business Overview
Table 61. Johnson and Johnson Cancer Biologics SWOT Analysis
Table 62. Johnson and Johnson Recent Developments
Table 63. Novartis Cancer Biologics Basic Information
Table 64. Novartis Cancer Biologics Product Overview
Table 65. Novartis Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 66. Novartis Cancer Biologics SWOT Analysis
Table 67. Novartis Business Overview
Table 68. Novartis Recent Developments
Table 69. Gilead Sciences Cancer Biologics Basic Information
Table 70. Gilead Sciences Cancer Biologics Product Overview
Table 71. Gilead Sciences Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 72. Gilead Sciences Business Overview
Table 73. Gilead Sciences Recent Developments
Table 74. Roche Cancer Biologics Basic Information
Table 75. Roche Cancer Biologics Product Overview
Table 76. Roche Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 77. Roche Business Overview
Table 78. Roche Recent Developments
Table 79. Bristol-Myers Squibb Cancer Biologics Basic Information
Table 80. Bristol-Myers Squibb Cancer Biologics Product Overview
Table 81. Bristol-Myers Squibb Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 82. Bristol-Myers Squibb Business Overview
Table 83. Bristol-Myers Squibb Recent Developments
Table 84. Amgen Cancer Biologics Basic Information
Table 85. Amgen Cancer Biologics Product Overview
Table 86. Amgen Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 87. Amgen Business Overview
Table 88. Amgen Recent Developments
Table 89. AstraZeneca Cancer Biologics Basic Information
Table 90. AstraZeneca Cancer Biologics Product Overview
Table 91. AstraZeneca Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 92. AstraZeneca Business Overview
Table 93. AstraZeneca Recent Developments
Table 94. Merck and Co Cancer Biologics Basic Information
Table 95. Merck and Co Cancer Biologics Product Overview
Table 96. Merck and Co Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 97. Merck and Co Business Overview
Table 98. Merck and Co Recent Developments
Table 99. Takeda Cancer Biologics Basic Information
Table 100. Takeda Cancer Biologics Product Overview
Table 101. Takeda Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 102. Takeda Business Overview
Table 103. Takeda Recent Developments
Table 104. Merck KGaA Cancer Biologics Basic Information
Table 105. Merck KGaA Cancer Biologics Product Overview
Table 106. Merck KGaA Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Recent Developments
Table 109. Seagen Cancer Biologics Basic Information
Table 110. Seagen Cancer Biologics Product Overview
Table 111. Seagen Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 112. Seagen Business Overview
Table 113. Seagen Recent Developments
Table 114. Eli Lilly Cancer Biologics Basic Information
Table 115. Eli Lilly Cancer Biologics Product Overview
Table 116. Eli Lilly Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 117. Eli Lilly Business Overview
Table 118. Eli Lilly Recent Developments
Table 119. Ono Pharmaceutical Cancer Biologics Basic Information
Table 120. Ono Pharmaceutical Cancer Biologics Product Overview
Table 121. Ono Pharmaceutical Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 122. Ono Pharmaceutical Business Overview
Table 123. Ono Pharmaceutical Recent Developments
Table 124. Pfizer Cancer Biologics Basic Information
Table 125. Pfizer Cancer Biologics Product Overview
Table 126. Pfizer Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 127. Pfizer Business Overview
Table 128. Pfizer Recent Developments
Table 129. GSK Cancer Biologics Basic Information
Table 130. GSK Cancer Biologics Product Overview
Table 131. GSK Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 132. GSK Business Overview
Table 133. GSK Recent Developments
Table 134. Exelixis Cancer Biologics Basic Information
Table 135. Exelixis Cancer Biologics Product Overview
Table 136. Exelixis Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 137. Exelixis Business Overview
Table 138. Exelixis Recent Developments
Table 139. Regeneron Cancer Biologics Basic Information
Table 140. Regeneron Cancer Biologics Product Overview
Table 141. Regeneron Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 142. Regeneron Business Overview
Table 143. Regeneron Recent Developments
Table 144. Innovent Cancer Biologics Basic Information
Table 145. Innovent Cancer Biologics Product Overview
Table 146. Innovent Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 147. Innovent Business Overview
Table 148. Innovent Recent Developments
Table 149. Hengrui Medicine Cancer Biologics Basic Information
Table 150. Hengrui Medicine Cancer Biologics Product Overview
Table 151. Hengrui Medicine Cancer Biologics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 152. Hengrui Medicine Business Overview
Table 153. Hengrui Medicine Recent Developments
Table 154. Global Cancer Biologics Sales Forecast by Region (2025-2032) & (K Units)
Table 155. Global Cancer Biologics Market Size Forecast by Region (2025-2032) & (M USD)
Table 156. North America Cancer Biologics Sales Forecast by Country (2025-2032) & (K Units)
Table 157. North America Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 158. Europe Cancer Biologics Sales Forecast by Country (2025-2032) & (K Units)
Table 159. Europe Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 160. Asia Pacific Cancer Biologics Sales Forecast by Region (2025-2032) & (K Units)
Table 161. Asia Pacific Cancer Biologics Market Size Forecast by Region (2025-2032) & (M USD)
Table 162. South America Cancer Biologics Sales Forecast by Country (2025-2032) & (K Units)
Table 163. South America Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 164. Middle East and Africa Cancer Biologics Consumption Forecast by Country (2025-2032) & (Units)
Table 165. Middle East and Africa Cancer Biologics Market Size Forecast by Country (2025-2032) & (M USD)
Table 166. Global Cancer Biologics Sales Forecast by Type (2025-2032) & (K Units)
Table 167. Global Cancer Biologics Market Size Forecast by Type (2025-2032) & (M USD)
Table 168. Global Cancer Biologics Price Forecast by Type (2025-2032) & (USD/Unit)
Table 169. Global Cancer Biologics Sales (K Units) Forecast by Application (2025-2032)
Table 170. Global Cancer Biologics Market Size Forecast by Application (2025-2032) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Cancer Biologics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cancer Biologics Market Size (M USD), 2019-2032
Figure 5. Global Cancer Biologics Market Size (M USD) (2019-2032)
Figure 6. Global Cancer Biologics Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Cancer Biologics Market Size by Country (M USD)
Figure 11. Cancer Biologics Sales Share by Manufacturers in 2023
Figure 12. Global Cancer Biologics Revenue Share by Manufacturers in 2023
Figure 13. Cancer Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Cancer Biologics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Cancer Biologics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Cancer Biologics Market Share by Type
Figure 18. Sales Market Share of Cancer Biologics by Type (2019-2024)
Figure 19. Sales Market Share of Cancer Biologics by Type in 2023
Figure 20. Market Size Share of Cancer Biologics by Type (2019-2024)
Figure 21. Market Size Market Share of Cancer Biologics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Cancer Biologics Market Share by Application
Figure 24. Global Cancer Biologics Sales Market Share by Application (2019-2024)
Figure 25. Global Cancer Biologics Sales Market Share by Application in 2023
Figure 26. Global Cancer Biologics Market Share by Application (2019-2024)
Figure 27. Global Cancer Biologics Market Share by Application in 2023
Figure 28. Global Cancer Biologics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Cancer Biologics Sales Market Share by Region (2019-2024)
Figure 30. North America Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Cancer Biologics Sales Market Share by Country in 2023
Figure 32. U.S. Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Cancer Biologics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Cancer Biologics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Cancer Biologics Sales Market Share by Country in 2023
Figure 37. Germany Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Cancer Biologics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Cancer Biologics Sales Market Share by Region in 2023
Figure 44. China Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Cancer Biologics Sales and Growth Rate (K Units)
Figure 50. South America Cancer Biologics Sales Market Share by Country in 2023
Figure 51. Brazil Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Cancer Biologics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Cancer Biologics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Cancer Biologics Production Market Share by Region (2019-2024)
Figure 62. North America Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 63. Europe Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 64. Japan Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 65. China Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 66. Global Cancer Biologics Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Cancer Biologics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Cancer Biologics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Cancer Biologics Market Share Forecast by Type (2025-2032)
Figure 70. Global Cancer Biologics Sales Forecast by Application (2025-2032)
Figure 71. Global Cancer Biologics Market Share Forecast by Application (2025-2032)
Figure 1. Product Picture of Cancer Biologics
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cancer Biologics Market Size (M USD), 2019-2032
Figure 5. Global Cancer Biologics Market Size (M USD) (2019-2032)
Figure 6. Global Cancer Biologics Sales (K Units) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Cancer Biologics Market Size by Country (M USD)
Figure 11. Cancer Biologics Sales Share by Manufacturers in 2023
Figure 12. Global Cancer Biologics Revenue Share by Manufacturers in 2023
Figure 13. Cancer Biologics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Cancer Biologics Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Cancer Biologics Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Cancer Biologics Market Share by Type
Figure 18. Sales Market Share of Cancer Biologics by Type (2019-2024)
Figure 19. Sales Market Share of Cancer Biologics by Type in 2023
Figure 20. Market Size Share of Cancer Biologics by Type (2019-2024)
Figure 21. Market Size Market Share of Cancer Biologics by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Cancer Biologics Market Share by Application
Figure 24. Global Cancer Biologics Sales Market Share by Application (2019-2024)
Figure 25. Global Cancer Biologics Sales Market Share by Application in 2023
Figure 26. Global Cancer Biologics Market Share by Application (2019-2024)
Figure 27. Global Cancer Biologics Market Share by Application in 2023
Figure 28. Global Cancer Biologics Sales Growth Rate by Application (2019-2024)
Figure 29. Global Cancer Biologics Sales Market Share by Region (2019-2024)
Figure 30. North America Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Cancer Biologics Sales Market Share by Country in 2023
Figure 32. U.S. Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Cancer Biologics Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Cancer Biologics Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Cancer Biologics Sales Market Share by Country in 2023
Figure 37. Germany Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Cancer Biologics Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Cancer Biologics Sales Market Share by Region in 2023
Figure 44. China Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Cancer Biologics Sales and Growth Rate (K Units)
Figure 50. South America Cancer Biologics Sales Market Share by Country in 2023
Figure 51. Brazil Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Cancer Biologics Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Cancer Biologics Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Cancer Biologics Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Cancer Biologics Production Market Share by Region (2019-2024)
Figure 62. North America Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 63. Europe Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 64. Japan Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 65. China Cancer Biologics Production (K Units) Growth Rate (2019-2024)
Figure 66. Global Cancer Biologics Sales Forecast by Volume (2019-2032) & (K Units)
Figure 67. Global Cancer Biologics Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Cancer Biologics Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Cancer Biologics Market Share Forecast by Type (2025-2032)
Figure 70. Global Cancer Biologics Sales Forecast by Application (2025-2032)
Figure 71. Global Cancer Biologics Market Share Forecast by Application (2025-2032)
